YU35498A - Sintetički hiv geni - Google Patents

Sintetički hiv geni

Info

Publication number
YU35498A
YU35498A YU35498A YU35498A YU35498A YU 35498 A YU35498 A YU 35498A YU 35498 A YU35498 A YU 35498A YU 35498 A YU35498 A YU 35498A YU 35498 A YU35498 A YU 35498A
Authority
YU
Yugoslavia
Prior art keywords
hiv genes
synthetic
synthetic hiv
codons
cell
Prior art date
Application number
YU35498A
Other languages
English (en)
Inventor
John W. Shiver
Mary-Ellen Davies
Daniel C. Fred
Margaret A. Lili
Helen C. Perry
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU35498A publication Critical patent/YU35498A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Obezbedjeni su sintetički DNK molekuli koji enkodiraju HIV gene i njihove modifikacije. Kodoni sintetičkih molekula koriste kodone koji su najpogodniji za ćeliju domaćina. Sintetički molekuli mogu da se upotrebe kao polinukleotidna vakcina koja obezbedjuje efikasnu imunoprofilaksu protiv HIV infekcije putem neutralizacionih antitela i ćelijom izazvanog imuniteta.
YU35498A 1996-02-22 1998-08-21 Sintetički hiv geni YU35498A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes

Publications (1)

Publication Number Publication Date
YU35498A true YU35498A (sh) 1999-07-28

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
YU35498A YU35498A (sh) 1996-02-22 1998-08-21 Sintetički hiv geni

Country Status (27)

Country Link
EP (1) EP0904380B1 (sh)
JP (1) JP2000505299A (sh)
KR (1) KR19990087126A (sh)
CN (1) CN1216064A (sh)
AR (1) AR005930A1 (sh)
AT (1) ATE309366T1 (sh)
AU (1) AU729231B2 (sh)
BG (1) BG102784A (sh)
BR (1) BR9707672A (sh)
CO (1) CO4600706A1 (sh)
CZ (1) CZ266798A3 (sh)
DE (1) DE69734585T2 (sh)
EE (1) EE9800257A (sh)
ES (1) ES2251734T3 (sh)
HR (1) HRP970092A2 (sh)
HU (1) HUP9901112A3 (sh)
ID (1) ID16021A (sh)
IL (1) IL125547A0 (sh)
IS (1) IS4814A (sh)
NO (1) NO983876L (sh)
NZ (1) NZ331161A (sh)
PE (1) PE43298A1 (sh)
PL (1) PL328730A1 (sh)
SK (1) SK112998A3 (sh)
TR (1) TR199801615T2 (sh)
WO (1) WO1997031115A2 (sh)
YU (1) YU35498A (sh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2258568A1 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
IL131131A0 (en) * 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
NZ338093A (en) 1997-04-04 2001-06-29 Patricia L Herman Methods and materials for making and using transgenic dicamba-degrading organisms
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
OA11520A (en) * 1997-10-20 2004-02-09 Genzyme Transgenics Corp Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
CA2369119A1 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
EP2278022A3 (en) 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expression vectors, transfection systems, and method of use thereof
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
US8754011B2 (en) 2006-10-16 2014-06-17 Monsanto Technology Llc Methods and compositions for improving plant health
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
DE69536091D1 (de) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
EE9800257A (et) 1999-02-15
TR199801615T2 (xx) 1998-11-23
EP0904380A2 (en) 1999-03-31
PL328730A1 (en) 1999-02-15
EP0904380B1 (en) 2005-11-09
BR9707672A (pt) 1999-04-13
PE43298A1 (es) 1998-08-29
NO983876L (no) 1998-10-21
DE69734585T2 (de) 2006-08-10
CZ266798A3 (cs) 1999-03-17
CN1216064A (zh) 1999-05-05
BG102784A (en) 1999-05-31
AU2124697A (en) 1997-09-10
HUP9901112A2 (hu) 1999-07-28
ATE309366T1 (de) 2005-11-15
KR19990087126A (ko) 1999-12-15
CO4600706A1 (es) 1998-05-08
HRP970092A2 (en) 1998-04-30
AU729231B2 (en) 2001-01-25
IS4814A (is) 1998-07-30
ES2251734T3 (es) 2006-05-01
WO1997031115A3 (en) 1997-10-09
AR005930A1 (es) 1999-07-21
NO983876D0 (no) 1998-08-21
HUP9901112A3 (en) 2001-06-28
NZ331161A (en) 2000-03-27
ID16021A (id) 1997-08-28
JP2000505299A (ja) 2000-05-09
DE69734585D1 (de) 2005-12-15
WO1997031115A2 (en) 1997-08-28
IL125547A0 (en) 1999-03-12
SK112998A3 (en) 2000-04-10

Similar Documents

Publication Publication Date Title
YU35498A (sh) Sintetički hiv geni
DE69836206D1 (de) Synthetische hiv gag gene
PT1212358E (pt) Genes sinteticos de papilomavirus humano
DK1252322T3 (da) Herpesvirusstamme til genterapi
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
ECSP056032A (es) Expresión optimizada de hpv 31 l1 en levadura
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
SE7806087L (sv) Forfarande for rening av nukleotidsekvenser lempliga som syntetiseringsmall i bakterier, mikroorganism innefattande dylik nukleotidsekvens samt rekombinant dna-overforingsvektor innefattande dylik nukleotid
MY101874A (en) Vaccine
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
ECSP972034A (es) Genes sinteticos vih
Elliott et al. Protein and nucleic acid analyses of influenza C viruses isolated from pigs and man
ES2045075T3 (es) Procedimiento para la preparacion de proteinas de plasmodium falciparum.
DE50308232D1 (de) Kosmetische oder pharmazeutische zubereitungen enthaltend nukleinsäuren auf der basis nicht-methylierter cpg-motive
PT980379E (pt) Oligonucleotidos quimericos e sua utilizacao
EA199800750A1 (ru) Синтетические гены вич
ATE346920T1 (de) Neues immunoregulatorisches protein lst-1
ATE69618T1 (de) Klonieren von superoxid-dismutase und expression in mikroorganismen.
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
AP1679A (en) Outer surface proteins, their genes, and their use.
IT1283950B1 (it) Oligonucleotidi in grado di modulare l'espressione del gene per la miotonina e usi di essi
FI945110A (fi) Tippuribakteerien rokotteiden valmistusmenetelmä